TMDX:NSD-TransMedics Group Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 94.18

Change

+1.93 (+2.09)%

Market Cap

USD 2.73B

Volume

0.98M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+3.92 (+5.86%)

USD 23.46B
PODD Insulet Corporation

+12.89 (+5.23%)

USD 17.22B
MASI Masimo Corporation

+4.70 (+2.98%)

USD 7.80B
BRKR Bruker Corporation

+1.08 (+2.85%)

USD 5.53B
IRTC iRhythm Technologies Inc

+2.14 (+2.08%)

USD 3.28B
PRCT Procept Biorobotics Corp

-3.14 (-5.64%)

USD 2.85B
QDEL Quidel Corporation

+2.05 (+7.97%)

USD 2.42B
LIVN LivaNova PLC

+0.93 (+2.56%)

USD 1.95B
NVCR Novocure Ltd

+0.78 (+4.39%)

USD 1.81B
UFPT UFP Technologies Inc

-1.26 (-0.61%)

USD 1.62B

ETFs Containing TMDX

LFSC F/m Emerald Life Sciences.. 4.41 % 0.00 %

+0.49 (+2.22%)

USD 0.05B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

+0.53 (+2.22%)

N/A
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+2.24 (+2.22%)

USD 0.16B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.03B
CIB0:XETRA VanEck Bionic Engineering.. 0.00 % 0.00 %

+0.21 (+2.22%)

N/A
CYBG:LSE VanEck Bionic Engineering.. 0.00 % 0.00 %

+0.11 (+2.22%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 51.05% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.05% 94% A 95% A
Trailing 12 Months  
Capital Gain 5.52% 76% C+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.52% 76% C+ 62% D
Trailing 5 Years  
Capital Gain 429.70% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 429.70% 100% F 95% A
Average Annual (5 Year Horizon)  
Capital Gain 72.31% 88% B+ 92% A
Dividend Return 72.31% 88% B+ 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 91.02% 38% F 21% F
Risk Adjusted Return 79.44% 99% N/A 91% A-
Market Capitalization 2.73B 94% A 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.